Recently, Wuhan Huiguan Biotechnology Co., Ltd. (hereinafter referred to as "Huiguan Biotechnology") completed its Pre-A+ financing round. This round was co-led by Optics Valley Industrial Investment and Yangtze River Capital Venture Capital, with joint participation from Optics Valley Financial Holdings. The funds will primarily be used for product R&D, market expansion, and team growth, further consolidating the company's leading position in the high-end biomedical imaging field.

Founded in September 2022, Huiguan Biotechnology was incubated from the team of Professor Fei Peng, a recipient of the National Science Fund for Distinguished Young Scholars at Huazhong University of Science and Technology. Leveraging its globally leading ultra-thin optical sectioning technology and AI-powered intelligent image algorithms, the company has launched innovative products including the world's first single-objective intelligent light-sheet microscope and a 3D digital intelligence pathology system. These provide全新的 three-dimensional imaging and data analysis solutions for life sciences, toxicological assessment, and clinical diagnosis.

Currently, Huiguan Biotechnology has built a microscopic imaging product matrix covering full-spectrum life science applications. Its related products have been deployed in multiple top-tier domestic universities, providing strong support for significant scientific breakthroughs and earning high recognition from both academia and the industry. The 3D digital intelligence pathology system, developed under the leadership of Huiguan Biotechnology, has been approved as a special project under the National Key R&D Program's "Disruptive Technological Innovation" initiative. As a representative technological innovation achievement of Hubei Province, it was inspected and received positive feedback from the General Secretary. Leveraging groundbreaking sub-100nm ultra-thin optical sectioning technology and integrating intelligent AI analysis algorithms, this device achieves a complete closed-loop workflow from sample pre-processing to 3D imaging to intelligent diagnosis, marking a transition from planar to three-dimensional pathology and pioneering a new paradigm of error-free and omission-free 3D pathological diagnosis. Ef Capital's Zhuohua Fund participated in its Pre-A financing round in January 2024.